Stauffer VL, et al. - The effectiveness and safety of galcanezumab after treatment cessation was examined among adults with episodic migraine enrolled in randomized double-blind, placebo-controlled, migraine prevention studies (EVOLVE-1; EVOLVE-2). From EVOLVE-1 and EVOLVE-2, 858 and 915 patients, respectively, were randomly allocated to galcanezumab 120 mg (initial 240-mg loading dose), galcanezumab 240 mg, or placebo, administered subcutaneously once monthly for 6 months. In the posttreatment periods, 740 patients (EVOLVE-1) and 830 (EVOLVE-2) patients were involved, and about 95% and 96% of patients, respectively, completed. Outcomes revealed a reduction in galcanezumab treatment effects in the posttreatment periods, however these did not return to baseline. Galcanezumab cessation led to no unexpected adverse events.